What’s in this issue?
PRIMARY CARE CLINICAL DIGEST
OCTOBER 6 2023
1. National Primary Care Communication Update on Measles October 6 2023
2. Claiming Guide for Crytosporidium Testing
3. National Data Platform Monthly Update September 2023
4. ACC Provider Update Primary Care
5. Enrolments Open for 2024 Ngā Manukura: Clinical Leadership Programme for Māori Nurses and Midwives
6. Ruruku News and Updates October 5 2023
7. Tablet Colour Changes for Recent Brand Change of Levlen to Oralcon
8. Supply Issue Affecting Dulaglutide and Liraglutide
9. Brand Change of Sumatriptan Injections
10. Goodfellow Continuing Professional Development
11. Pharmac: Supply Updates for Pharmacists October 6 2023 and Updates for Pharmacists in General Practice September 29 2023
12. Top Weekend Viewing National Primary Care Communication Update on Measles October 6 2023
See link here
• A measles case has been identified in Northland. This case has no history of international travel and no contact with the previous cases in the past fortnight.
• Check HealthPathways for further up-to-date measles assessment and management information.
• Resources can be found on the Te Whatu Ora website as outlined in the attached update.
Claiming Guide for Crytosporidium Testing
See information here
National Data Platform Monthly Update September 2023
See email
• Please see attached the confirmed claiming guide for cryptosporidium testing.
• Any queries please contact ncr.spoc@health.govt.nz
• Please see the first National Data Platform (NDP) monthly reporting email. This issue covers:
o September Highlights and October Work Plan
o NDP Build and content
o How NDP is run
o Engagement and updates
o Challenges and timeline
ACC Provider Update
Primary Care ACC Provider Update
• Included in this issue are the following. See the update for more information:
o Webinar: How to invoice under the Rural General Practice Services contract
o Expert Advisory Group announced for Primary Acute Care
o Reminder about only providing telehealth in New Zealand
o New video: The basics of maternal birth injury cover
o Update on the Rehabilitation Improvement Group (RIG) work
Enrolments Open for 2024
• There are 25 places available for each cohort.
Ngā Manukura: Clinical Leadership Programme for Māori Nurses and Midwives
View online
Ruruku News and Updates
October 5 2023
View online
• See here for details of the programme, participant eligibility, enrolment form, costs, dates and other relevant information.
• Any queries, please contact tania@digitalindigenous.co.nz
• This issue covers the following including the New National Clinical Networks EOI. Further information can be found in the link:
o Message from Chief Executives
o Stakeholder virtual hui recording - 4 October
o New National Clinical Networks EOIs
o Aotearoa Immunisation Register (AIR)
o Tamariki immunisation schedule
Tablet Colour Changes for Recent Brand Change of Levlen to Oralcon
View online
• As a result of a tender brand change, Viatris’ brand of ethinyloestradiol with levonorgestrel 30mcg/150mcg (Oralcon 30 ED) was awarded Principal Supplier Status effective from August 1 2023.
• See webpage to support consumers with brand change and any questions, please email enquiry@pharmac.govt.nz
Supply Issue Affecting
Dulaglutide and Liraglutide
• There are global constraints on the supply of GLP-1 agonists. Suppliers of both dulaglutide (Eli Lilly) and liraglutide (Novo Nordisk) do not have enough stock to cater to the rapid increase in demand. Pharmac are trying to preserve dulaglutide and liraglutide for people already taking it for type 2 diabetes.
• To safeguard stock for people currently using dulaglutide and liraglutide, Pharmac strongly urge the consideration of other blood glucose-lowering medicines for all new patients.
• Pharmac are looking to identify what additional steps can be taken to ensure continued access to medicine during this global supply issue.
• Any questions, please contact the following:
o dulaglutide stock, contact Eli Lilly.
o liraglutide stock, contact Novo Nordisk.
o funding, email enquiry@pharmac.govt.nz
Brand Change of Sumatriptan Injections
See factsheet here
• As a result of a tender brand change, Douglas’ brand of Sumatriptan injections (Clustran) has been awarded Principal Supplier Status effective from November 1 2023.
• GSK’s Imigran brand will be delisted from the Pharmaceutical Schedule on May 1 2024.
• To aid with counselling people taking sumatriptan injections on this brand change a range of resources have been created and a fact sheet is also attached.
• Any questions, please email enquiry@pharmac.govt.nz
Goodfellow Continuing Professional Development
View online
Pharmac:
• View online to see webinars and events being offered by the Goodfellow Unit.
• View online to see the latest information across both these updates:
Supply Updates for Pharmacists - October 6 2023
View online
Updates for Pharmacists in General PracticeSeptember 29 2023
View online
o New medicine notices
o Supply and updated issues
o Notifications
o Resolved issues
o Recent decisions
o Open consultations
o Monthly updates
o Increase in the number of supply issues
o Expressions of Interest for Pharmac’s Advisory Committees
Top Weekend Viewing • Spring, the season associated with budding love! Bit of a cliché but there are a few ‘love’ stories, one historic, one light-hearted and one about the love of the beautiful game.
o Queen Charlotte: A Bridgerton Story (Netflix) – Charlotte meets and marries King George and this minseries explores their marriage and his mental illness. watch trailer
o Love is in the Air (Netflix) – movie about a pilot fighting to keep her family business afloat starts to fall for the man sent to ground her operation, forcing her to choose between her heart and her family. watch trailer
o Beckham (Netflix) –this docuseries follows David Beckham's meteoric rise from humble beginnings to global football stardom and his relationship with his wife Victoria. watch trailer